DOVA Dova Pharmaceuticals Inc

---

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

---

This Amendment No.2 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO (as amended and together with any subsequent amendments and supplements thereto, the “Schedule TO”), filed with the Securities and Exchange Commission (“SEC”) on October 11, 2019, by Dragonfly Acquisition Corp., a Delaware corporation (“Purchaser”), a wholly owned subsidiary of Dragonfly Holding Corp. (“HoldCo”), HoldCo, a Delaware corporation and a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (“Sobi”), and Sobi, a Swedish public limited liability company.  The Schedule TO relates to the tender offer by Purchaser for all of the outstanding shares of common stock, par value $0.001 per share (“Shares”), of Dova Pharmaceuticals, Inc., a Delaware corporation (“Dova”), for (i) $27.50 per Share, net to the seller thereof in cash, without interest and subject to any applicable withholding taxes, plus (ii) one contractual contingent value right per Share which represents the right to receive a contingent payment of $1.50 in cash, without interest and subject to any applicable withholding taxes, if a specified milestone is achieved, upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 11, 2019 (together with any amendments and supplements thereto, the “Offer to Purchase”) and in the related letter of transmittal (together with any amendments and supplements thereto, the “Letter of Transmittal”), copies of which are attached hereto as exhibits (a)(1)(A) and (a)(1)(B), respectively.

The information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated by reference herein in response to Items 1 through 9 and Item 11 of the Schedule TO, and the information in the Offer to Purchase is supplemented by the information specifically provided in this Amendment.

Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Offer to Purchase or in the Schedule TO.

Item 11.  Additional Information.

Item 11 of the Schedule TO, to the extent such Item incorporates by reference the information contained in the Offer to Purchase, is hereby amended and supplemented to include the following:

“At one minute after 11:59 p.m., Eastern Time (12:00 midnight), on November 8, 2019, the Offer expired as scheduled. The Depositary has advised Purchaser that, as of the expiration of the Offer, a total of 26,312,870 Shares were validly tendered (and not validly withdrawn) pursuant to the Offer, representing approximately 91.2% of the currently issued and outstanding Shares. As a result, the Minimum Condition has been satisfied. In addition, the Depositary has also advised Purchaser that, as of such time, Notices of Guaranteed Delivery had been received for 1,393,166 Shares, representing approximately 4.8% of the currently issued and outstanding Shares. All Shares that were validly tendered and not validly withdrawn pursuant to the Offer have been accepted for payment.

Following the expiration of the Offer and acceptance of the Shares for payment, on November 12, 2019, pursuant to the terms of the Merger Agreement and to Section 251(h) of the DGCL, Sobi consummated the Merger without a meeting of Dova stockholders. Pursuant to the Merger Agreement, at the Effective Time, Purchaser was merged with and into Dova, with Dova continuing as the surviving corporation and an indirect wholly owned subsidiary of Sobi. At the Effective Time, each Share issued and outstanding immediately prior to the Effective Time, other than (i) Shares held by Sobi or Purchaser or any other direct or indirect wholly owned subsidiary of Sobi or Shares held by Dova or any of its subsidiaries and (ii) Shares held by Dova stockholders who properly exercise and perfect their appraisal rights under Section 262 of the DGCL with respect to such Shares, was converted into the right to receive the Merger Consideration. The Shares will be delisted from the NASDAQ Global Market and will be deregistered under the Exchange Act.

On November 9, 2019, Sobi issued press release announcing the expiration and results of the Offer, and on November 12, 2019, Sobi issued a press release announcing the consummation of the Merger. Those press releases are attached as Exhibits (a)(5)(D) and (a)(5)(E), respectively, and are incorporated by reference herein.”

---

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	DRAGONFLY ACQUISITION CORP.
	By:	/s/ HENRIK STENQVIST
		Name:	Henrik Stenqvist
		Title:	Chief Financial Officer, Vice President and Treasurer
		Date:	November 12, 2019